Wai Yuen Tong Medicine Holdings Limited (0897.HK)
HKD 0.32
(-5.88%)
HKD 0.32
(-5.88%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 460.94 Million HKD | -73.88% |
| 2022 | 1.76 Billion HKD | -2.19% |
| 2021 | 1.8 Billion HKD | 1.95% |
| 2020 | 1.76 Billion HKD | -8.88% |
| 2019 | 1.94 Billion HKD | 127.9% |
| 2018 | 852.22 Million HKD | -8.07% |
| 2017 | 927.01 Million HKD | 22.09% |
| 2016 | 759.3 Million HKD | 2.79% |
| 2015 | 738.68 Million HKD | 34.28% |
| 2014 | 550.09 Million HKD | 40.61% |
| 2013 | 391.21 Million HKD | 48.88% |
| 2012 | 262.77 Million HKD | 87.54% |
| 2011 | 140.12 Million HKD | 17.98% |
| 2010 | 118.76 Million HKD | 145.12% |
| 2009 | 48.45 Million HKD | -45.18% |
| 2008 | 88.39 Million HKD | -61.9% |
| 2007 | 232 Million HKD | 291.41% |
| 2006 | 59.27 Million HKD | -55.45% |
| 2005 | 133.06 Million HKD | -16.72% |
| 2004 | 159.78 Million HKD | 110.46% |
| 2003 | 75.92 Million HKD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 Q2 | 1.5 Billion HKD | 0.0% |
| 2023 FY | 460.94 Million HKD | -73.88% |
| 2023 Q4 | 460.94 Million HKD | 0.0% |
| 2022 Q2 | 1.75 Billion HKD | 0.0% |
| 2022 FY | 1.76 Billion HKD | -2.19% |
| 2022 Q4 | 1.76 Billion HKD | 0.0% |
| 2021 Q4 | 1.8 Billion HKD | 0.0% |
| 2021 Q2 | 1.83 Billion HKD | 0.0% |
| 2021 FY | 1.8 Billion HKD | 1.95% |
| 2020 Q4 | 1.76 Billion HKD | 0.0% |
| 2020 FY | 1.76 Billion HKD | -8.88% |
| 2020 Q2 | 1.8 Billion HKD | 0.0% |
| 2019 FY | 1.94 Billion HKD | 127.9% |
| 2019 Q2 | 1.06 Billion HKD | 0.0% |
| 2019 Q4 | 2.31 Billion HKD | 0.0% |
| 2018 Q4 | 852.22 Million HKD | 0.0% |
| 2018 Q2 | 929.62 Million HKD | 0.0% |
| 2018 FY | 852.22 Million HKD | -8.07% |
| 2017 FY | 927.01 Million HKD | 22.09% |
| 2017 Q2 | 714.41 Million HKD | 0.0% |
| 2017 Q4 | 927.01 Million HKD | 0.0% |
| 2016 Q4 | 759.3 Million HKD | 0.0% |
| 2016 Q2 | 773.75 Million HKD | 0.0% |
| 2016 FY | 759.3 Million HKD | 2.79% |
| 2015 Q4 | 738.68 Million HKD | 0.0% |
| 2015 Q2 | 594.34 Million HKD | 0.0% |
| 2015 FY | 738.68 Million HKD | 34.28% |
| 2014 Q3 | - HKD | -100.0% |
| 2014 FY | 550.09 Million HKD | 40.61% |
| 2014 Q1 | - HKD | -100.0% |
| 2014 Q4 | 550.09 Million HKD | 0.0% |
| 2014 Q2 | 465.72 Million HKD | 0.0% |
| 2013 Q1 | - HKD | -100.0% |
| 2013 Q4 | 391.21 Million HKD | 0.0% |
| 2013 FY | 391.21 Million HKD | 48.88% |
| 2013 Q3 | - HKD | -100.0% |
| 2013 Q2 | 347.17 Million HKD | 0.0% |
| 2012 Q1 | - HKD | -100.0% |
| 2012 Q4 | 262.77 Million HKD | 0.0% |
| 2012 Q3 | - HKD | -100.0% |
| 2012 FY | 262.77 Million HKD | 87.54% |
| 2012 Q2 | 129.98 Million HKD | 0.0% |
| 2011 Q4 | 140.12 Million HKD | 0.0% |
| 2011 FY | 140.12 Million HKD | 17.98% |
| 2011 Q2 | 138.05 Million HKD | 0.0% |
| 2010 FY | 118.76 Million HKD | 145.12% |
| 2010 Q2 | 41.3 Million HKD | 0.0% |
| 2010 Q4 | 118.76 Million HKD | 0.0% |
| 2009 Q4 | 48.45 Million HKD | 0.0% |
| 2009 FY | 48.45 Million HKD | -45.18% |
| 2008 FY | 88.39 Million HKD | -61.9% |
| 2007 FY | 232 Million HKD | 291.41% |
| 2006 FY | 59.27 Million HKD | -55.45% |
| 2005 FY | 133.06 Million HKD | -16.72% |
| 2004 FY | 159.78 Million HKD | 110.46% |
| 2003 FY | 75.92 Million HKD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 6.8 Million HKD | -6668.709% |
| Grand Pharmaceutical Group Limited | 3.4 Billion HKD | 86.46% |
| Extrawell Pharmaceutical Holdings Limited | 120.41 Million HKD | -282.816% |
| Qianhai Health Holdings Limited | 487 Thousand HKD | -94550.719% |
| Lee's Pharmaceutical Holdings Limited | 204.14 Million HKD | -125.8% |
| Essex Bio-Technology Limited | 294.02 Million HKD | -56.774% |
| Tongfang Kontafarma Holdings Limited | 333.82 Million HKD | -38.082% |
| PuraPharm Corporation Limited | 424.77 Million HKD | -8.517% |
| SSY Group Limited | 3.37 Billion HKD | 86.339% |
| JBM (Healthcare) Limited | 133.4 Million HKD | -245.521% |
| Jacobson Pharma Corporation Limited | 749.37 Million HKD | 38.489% |
| China Resources Pharmaceutical Group Limited | 85.84 Billion HKD | 99.463% |